Switch Study of Existing Atypical Antipsychotics to Bifeprunox
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and tolerability of switching subjects with schizophrenia
or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Phase:
Phase 3
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborators:
H. Lundbeck A/S Wyeth is now a wholly owned subsidiary of Pfizer